Treatment of Celiac Disease in Individuals with HLA-DQ2
Understanding HLA-DQ2 and Celiac Disease
- HLA-DQ2 is present in approximately 95% of celiac disease patients and represents the primary genetic risk factor for developing the condition 2
- The presence of HLA-DQ2 is necessary but not sufficient for developing celiac disease, as approximately 25-30% of the general white population carries this genetic marker 3
- HLA-DQ2 testing has excellent negative predictive value (close to 100%) but poor positive predictive value due to its high prevalence in the general population 2
Core Treatment Approach
- Complete elimination of all gluten-containing grains (wheat, rye, barley) and their hybrids (kamut, triticale) is mandatory 4
- Consultation with a registered dietitian experienced in celiac disease management is essential for nutritional assessment 5
- Meal planning guidance is crucial for individuals with celiac disease 6
Monitoring and Follow-up
- Regular follow-up is necessary to confirm clinical response to the GFD 1
- Follow-up serology should be performed at 6 and 12 months after diagnosis, and yearly thereafter 7
- Persistent positive serology usually indicates ongoing intestinal damage and continued gluten exposure 7
Nutritional Considerations
- The GFD must be nutritionally balanced to prevent deficiencies 4
- Patients should be tested for micronutrient deficiencies at diagnosis (iron, folate, vitamin D, vitamin B12) 5
- Treatment of identified nutritional deficiencies is essential 1
- Bone mineral density assessment is recommended to evaluate for osteoporosis 1
Common Challenges and Pitfalls
- Cross-contamination during food preparation is a common challenge for individuals with celiac disease 4
- Travel challenges can be a social and psychological barrier to adherence 1
Emerging Treatments (Not Yet Approved)
- Subcutaneous injection of dominant immunotoxic gliadin peptides is being studied as a potential treatment for celiac disease 8, 9
- Gluten-degrading enzymes (prolyl endopeptidases) are being investigated as a potential treatment for celiac disease 9
- Tight junction regulators like larazotide acetate are being studied as a potential treatment for celiac disease 9
- Transglutaminase 2 (TG2) inhibitors are being investigated as a potential treatment for celiac disease 9